Christina Isacson
Director/Board Member chez Tagworks Pharmaceuticals BV
Profil
Christina Isacson is a Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical sector.
Christina has spent nearly 20 years in the biotech industry across operational roles and in venture capital.
She brings experience in creating, launching, building and operating early stage biotechnology companies including Magenta Therapeutics (NASDAQ:MGTA) and Decibel Therapeutics (NASDAQ:DBTX).
Before joining Lightstone in 2021, Christina was part of the founding team and Chief Business Officer at Magenta Therapeutics where she was accountable for portfolio strategy and management, program management, business development, alliance management and commercial strategy.
Prior to Magenta, Christina was Principal at Third Rock Ventures, an early-stage life sciences venture capital firm.
At Third Rock, Christina focused on new company formation, due diligence, and led business development efforts more broadly on behalf of Third Rock.
Prior to being part of the founding teams of Magenta and Decibel, Christina held operational roles at Ironwood Pharmaceuticals (NASDAQ:IRWD) in corporate development.
In addition, she has held venture roles with Boston University’s Technology Development Fund and with Accelerator Corp (Fund I).
Originally trained as a Ph.D.
in Neuroscience, leading the integration of science and medicine with business is a fundamental objective in her career.
Postes actifs de Christina Isacson
| Sociétés | Poste | Début |
|---|---|---|
LSV CAPITAL MANAGEMENT LLC
 LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management LLC (Lightstone Ventures) is a venture capital firm founded in 2012. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 01/03/2021 |
Tagworks Pharmaceuticals BV
 Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011. | Director/Board Member | 01/01/2023 |
Anciens postes connus de Christina Isacson
| Sociétés | Poste | Fin |
|---|---|---|
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | 01/03/2021 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Corporate Officer/Principal | 01/08/2016 |
| IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/09/2013 |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Christina Isacson
| McGill University | Undergraduate Degree |
| Tufts University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Edimer Pharmaceuticals, Inc.
Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Tagworks Pharmaceuticals BV
Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
LSV CAPITAL MANAGEMENT LLC
LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management LLC (Lightstone Ventures) is a venture capital firm founded in 2012. The firm is headquartered in Menlo Park, California. | Finance |
